Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
NCT ID: NCT03004326
Last Updated: 2026-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2017-01-31
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
VCRC Tissue Repository
NCT02967068
One-Time DNA Study for Vasculitis
NCT01241305
Belimumab in Remission of VASculitis
NCT01663623
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis
NCT00059748
Autoimmune and Autoinflammatory Genetics Study
NCT06004349
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A punch skin biopsy at a site of active vasculitis will be the source of material for histopathologic and transcriptomic evaluation. The histopathology of cutaneous vasculitis will be characterized using a standardized approach.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a suspected or confirmed diagnosis of:
* Cryoglobulinemic vasculitis (CV)
* Drug-induced vasculitis
* Eosinophilic granulomatosis with polyangiitis (EGPA)
* IgA vasculitis
* Isolated cutaneous vasculitis
* Granulomatosis with polyangiitis (GPA)
* Microscopic polyangiitis (MPA)
* Polyarteritis nodosa (PAN)
* Urticarial vasculitis
* Be willing and able to provide written informed consent (or assent for those under
Exclusion Criteria
* Considered not to be a candidate for a biopsy or have a higher risk of developing an infection, bleeding, etc., from the biopsy, or a doctor believes that the risks for you participating in this study do not outweigh the potential benefit of learning information from your biopsy
* You have a neutrophil count (type of white blood cell) less than 1500/mm3, platelet count less than 50,000/mm3, or a hemoglobin less than 7 g/dL
* You have an uncontrolled disease that could prevent you from completing the study procedures
* You have an active infection at or near the potential biopsy site, have poor circulation, or have bony prominence or other structure that would increase your risk of complications if you participated in this study
* You are pregnant or nursing
* You are not able to provide informed consent
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
National Center for Advancing Translational Sciences (NCATS)
NIH
Office of Rare Diseases Research (ORDR)
UNKNOWN
Peter Merkel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter Merkel
Chief, Division of Rheumatology Professor of Medicine and Epidemiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Micheletti, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Peter Grayson, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
The National Institute of Arthritis and Musculoskeletal and Skin Diseases
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Los Angeles
Los Angeles, California, United States
Boston University School of Medicine
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Cleveland Clinic
Cleveland, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Utah
Salt Lake City, Utah, United States
University of Virginia
Charlottesville, Virginia, United States
St. Joseph's Healthcare
Hamilton, Ontario, Canada
University of Toronto Mount Sinai Hospital
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VCRC5563
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.